We found that EGF/ERBB signaling genes made up a larger proportion of cancer signaling genes in GBM and Her2 breast cancer signaling pathways, compared with those in the Wnt-β-catenin signaling pathway (Supplementary Table S3). This evidence concerns the gene ERBB2 and glioblastoma.